Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00208780 · ClinicalTrials.gov registry record · Early Phase 1
Effects of Tetrahydrobiopterin on Blood Pressure
A Early Phase 1 study, sponsored by Emory University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 24
- Enrollment target
NCT00208780 is a Early Phase 1 study that has completed, run by Emory University. The registered enrollment target is 24 participants.
The verdict
NCT00208780, a Early Phase 1 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
Tetrahydrobiopterin (BH4) is a cofactor for the nitric oxide (NO) synthase enzymes, such that its insufficiency results in uncoupling of the enzyme, leading to release of superoxide rather than NO in disease states, including hypertension. We hypothesized that oral BH4 will reduce arterial blood pressure (BP) and improve endothelial function in hypertensive subjects. Oral BH4 was given to subjects with poorly controlled hypertension (BP \>135/85 mm Hg) and weekly measurements of BP and endothelial function made. In Study 1, 5 or 10 mg kg-1 day-1 of BH4 (n=8) was administered orally for 8 weeks, and in Study 2, 200 and 400 mg of BH4 (n=16) was given in divided doses for 4 weeks
Interventions
- DRUG Tetrahydrobiopterin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2004-12 |
| Est. Completion | 2005-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00208780
The ClinicalTrials.gov registry entry for NCT00208780 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tetrahydrobiopterin is the first listed.
NCT00208780 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00208780 about?
NCT00208780 is a clinical study titled "Effects of Tetrahydrobiopterin on Blood Pressure". Tetrahydrobiopterin (BH4) is a cofactor for the nitric oxide (NO) synthase enzymes, such that its insufficiency results in uncoupling of the enzyme, leading to release of superoxide rather than NO in disease states, including hypertension. We hypothesized that oral BH4 will reduce arterial blood pre...
What is the current status of trial NCT00208780?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 24 participants. The study started on 2004-12. Estimated completion is 2005-12.
What interventions are being tested in trial NCT00208780?
The interventions under investigation include: Tetrahydrobiopterin (DRUG).
Who is sponsoring clinical trial NCT00208780?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.